ATTRv-PN

AstraZeneca stays on course to challenge Alnylam with 66-week rare disease data
Fierce Biotech
Mon, 03/27/23 - 10:22 am
AstraZeneca
Ionis Pharmaceuticals
aplontersen
Alnylam
Onpattro
clinical trials
ATTRv-PN
Data drip sheds little light on how Ionis, AstraZeneca compare to Alnylam in rare disease
Fierce Biotech
Wed, 09/7/22 - 10:18 am
AstraZeneca
Ionis Pharmaceuticals
Alnylam
antisense
ATTRv-PN
aplontersen